Drug Type Small molecule drug |
Synonyms 1-(2-(Ethylsulfonyl)ethyl)-2-methyl-5-nitroimidazole, Timidazole, Tinidazole (JP17/USP/INN) + [17] |
Target |
Action modulators |
Mechanism DNA modulators(DNA modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (01 Jan 1994), |
RegulationOrphan Drug (United States) |
Molecular FormulaC8H13N3O4S |
InChIKeyHJLSLZFTEKNLFI-UHFFFAOYSA-N |
CAS Registry19387-91-8 |
Start Date01 Dec 2025 |
Sponsor / Collaborator |
Start Date23 Jul 2025 |
Sponsor / Collaborator |
Start Date01 Aug 2024 |
Sponsor / Collaborator- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01426 | Tinidazole |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Bacterial Vaginosis | United States | 21 May 2007 | |
Amebiasis | United States | 17 May 2004 | |
Giardiasis | United States | 17 May 2004 | |
Trichomonas Infections | United States | 17 May 2004 | |
Bacterial Infections | China | 01 Jan 1994 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Mycoplasma genitalium infection | Phase 2 | United States | 23 Jul 2025 | |
non-gonococcal urethritis (NGU) | Phase 2 | United States | 23 Jul 2025 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 4 | 593 | (Tinidazole 1 gm) | wqlpkswdxm = zjwuugtvzd maeoqhpwyg (cqlrpnsqzu, kbahnakkkj - dqehdwlxtq) View more | - | 23 Jun 2011 | ||
(Control) | lyhzkcvzhq = rwkbytweup acqloqkcoz (robqyxhxyl, bakklazljx - zilgebczxj) | ||||||
Phase 3 | 235 | Tinidazole 1 g once daily for 5 days | aztiyvqgdk(onfuqbtgos) = knmtwjfucs wbzogypvdh (yucfbxegrv ) | - | 01 Aug 2007 | ||
Tinidazole 2 g once daily for 2 days | aztiyvqgdk(onfuqbtgos) = duxtofrfpl wbzogypvdh (yucfbxegrv ) |